Compare Baker Hughes Co (BKR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Zimmer Biomet Holdings Inc — how do they compare? Baker Hughes Co trades at $64.67 (market cap $64.34B), while Zimmer Biomet Holdings Inc trades at $95.77 (market cap $18.55B). The key difference: Baker Hughes Co is far larger — about 3.5× Zimmer Biomet Holdings Inc's market cap, and Baker Hughes Co pays the higher dividend (1.42%). Which is the better fit depends on your goals.
| BKR | ZBH | |
|---|---|---|
Market Cap | $64.34B | $18.55B |
Sector | Energy | Health |
52-Week High | $69.67 | $107.71 |
52-Week Low | $42.51 | $79.58 |
Enterprise Value | $64.86B | $25.61B |
Dividend Yield | 1.42% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.07, up 4.09% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.64 exceeding expectations. Recent contract wins in subsea systems and LNG technology, along with the Chart Industries acquisition, position the company for growth despite modest oil & gas spending headwinds. Operating cash flow reached $3.81 billion in 2025, supporting financial stability.
BKR presents a favorable risk-reward profile with 66.7% analyst buy ratings and a $73.25 consensus target offering 14% upside. Key risks include integration challenges from acquisitions and oil market volatility, but strong backlog and margin expansion support the bullish case. The stock remains attractive for investors seeking energy technology exposure with solid cash flow generation.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
